Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

This study has been completed.

Sponsor:

Information provided by:

Eli Lilly and Company

ClinicalTrials.gov Identifier:

NCT00051909

First received: January 17, 2003

Last updated: July 18, 2006

Last verified: July 2006

History of Changes

Purpose

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: LY451395	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:


Estimated Enrollment:	200
Study Start Date:	November 2002
Estimated Study Completion Date:	June 2003

Eligibility


Ages Eligible for Study:	50 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Must have a clinical diagnosis of Alzheimer's Disease
Must be at least 50 years of age
Must fluently read and speak English
Must have a reliable caregiver

Exclusion Criteria:

Has serious health problems other than Alzheimer's Disease
Cannot swallow whole pills
Has had a menstrual period in the last two years
Takes insulin for diabetes
Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051909

Locations


United States, California

Beverly Hills, California, United States

Fresno, California, United States
United States, Florida

Boca Raton, Florida, United States

Fort Lauderdale, Florida, United States

Miami Beach, Florida, United States
United States, Massachusetts

Boston, Massachusetts, United States
United States, Oklahoma

Oklahoma City, Oklahoma, United States

Tulsa, Oklahoma, United States
United States, Texas

Wichita Falls, Texas, United States

Sponsors and Collaborators

Eli Lilly and Company

More Information


ClinicalTrials.gov Identifier:	NCT00051909 History of Changes
Other Study ID Numbers:	6764 H6N-MC-LEAM
Study First Received:	January 17, 2003
Last Updated:	July 18, 2006
Health Authority:	United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:


Alzheimer's Disease

Additional relevant MeSH terms:


Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases	Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

ClinicalTrials.gov processed this record on September 28, 2016

To Top